

REGENERON PHARMACEUTICALS INC

Form 8-K

November 02, 2007

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 2, 2007 (November 1, 2007)

**REGENERON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)**

New York

000-19034

13-3444607

(State or other jurisdiction of
Incorporation)

(Commission File No.)

(IRS Employer Identification No.)

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707

(Address of principal executive offices, including zip code)

(914) 347-7000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 8.01 Other Events.

Item 9.01 Financial Statements and Exhibits.

SIGNATURES

Exhibit Index

EX-99.1: PRESS RELEASE

Table of Contents

Item 8.01 Other Events.

On November 1, 2007, Regeneron Pharmaceuticals, Inc. issued a press release announcing that it received notification earlier in the day from the U.S. Food and Drug Administration (FDA) that the action date for FDA's priority review of the Biologics License Application (BLA) for rilonacept, the Interleukin-1 (IL-1) Trap, for the long-term treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) has been extended three months to February 29, 2008. A copy of this press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated November 1, 2007.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 2, 2007

REGENERON PHARMACEUTICALS, INC.

By: /s/ Stuart Kolinski

Name: Stuart Kolinski

Title: Senior Vice President and General
Counsel

Table of Contents

Exhibit Index

Number	Description
99.1	Press Release dated November 1, 2007